Clinical trials
Recurrent or Metastatic Solid Tumors clinical trials
Below are recruiting recurrent or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 3,299 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04501718RecruitingPhase 2
Study of apatinib plus chemotherapy for recurrent childhood medulloblastoma
This trial tests whether adding apatinib to temozolomide and etoposide helps children whose medulloblastoma has come back. It aims to slow the tumor and improve outcomes after standard treatments.
BeijingAges 2–21 - NCT04501705Recruiting
Apatinib for adults with recurring atypical or malignant meningioma
This trial tests whether apatinib can shrink or control recurring atypical/malignant meningioma that has come back after surgery and radiation. It focuses on adults with measurable regrowth on MRI and good overall health to safely take an oral medicine.
Beijing, Beijing MunicipalityAges 18–70 - NCT07714668RecruitingPhase 2
Combination therapy for recurrent ovarian cancer
This study tests a new combination treatment for ovarian cancer that has come back after earlier treatment. It aims to see if the combination can shrink tumors or slow the disease, and it may be an option for people whose cancer has become resistant to platinum-based chemotherapy.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06641544RecruitingPhase 4
Testing different drug combos for HER2-positive breast cancer
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Shanwei, GuangdongAges 18–70 - NCT04979156Recruiting
Laser removal of bladder tumors in one piece
This trial studies using a specific laser technique to remove bladder tumors “en bloc” (in one piece) during a procedure. It may help reduce leftover tumor tissue and improve how safely the tumor can be removed for people with certain small, papillary bladder tumors.
Kansas City, KansasAges 18 years+ - NCT04547166RecruitingPhase 2/Phase 3
New targeted immune drug plus bevacizumab and chemo for colon cancer
This trial studies serplulimab (an immune-related drug) together with bevacizumab and chemotherapy to treat metastatic colorectal (colon) cancer that cannot be removed with surgery. It aims to see whether this combination improves outcomes and is safe.
Guangzhou, GuangdongAges 18–75 - NCT05683886RecruitingPhase 2
Study KC1036 for advanced thymus tumors after chemotherapy
This trial tests KC1036 in people with advanced thymoma or thymic carcinoma whose cancer came back or spread after their first standard chemotherapy. It may offer a new treatment option when earlier treatment no longer worked.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05260385RecruitingPhase 1/Phase 2
Study drug KC1036 for advanced digestive cancers
This early-phase study tests whether KC1036 can treat advanced digestive system cancers that have come back or spread after standard treatment. It may help people by shrinking tumors or slowing growth, and it will also check safety and side effects.
BeijingAges 18–75 - NCT07701486RecruitingPhase 1/Phase 2
Testing more frequent VCN-01 with standard chemo for new pancreatic cancer
This study tests a more frequent schedule of the experimental drug VCN-01 along with standard chemotherapy (nab-paclitaxel and gemcitabine) for people newly diagnosed with pancreatic cancer that has spread. The goal is to see if the virus-based therapy can help shrink tumors better.
Madrid, MadridAges 18 years+ - NCT06611345Recruiting
Tumor-treating fields with immunotherapy and chemo for bile duct cancer
This trial is testing a new combination of treatments—a wearable device that sends electric fields to the tumor area (tumor-treating fields) plus immunotherapy (durvalumab) and chemotherapy (gemcitabine/cisplatin)—for people with advanced bile duct or gallbladder cancer. It may be an option if you haven't had chemotherapy for advanced disease before.
HefeiAges 18–75 - NCT07686380RecruitingPhase 2
IL-15 treatment with or without vaccine for prostate cancer
This trial tests a drug called IL-15 superagonist (with or without a vaccine) for men whose prostate cancer has come back (shown by rising PSA) after they already had targeted radiation therapy. The goal is to see if this treatment can lower or control PSA levels.
Bethesda, MarylandAges 18–120 - NCT07680764RecruitingPhase 2
Imzokitug plus pumitamig and chemo for first-line advanced lung cancer
This trial tests a new combination of drugs (imzokitug, pumitamig, and platinum-doublet chemotherapy) as a first treatment for advanced or metastatic non-small cell lung cancer that has not spread to the brain. The goal is to see if adding imzokitug makes the standard treatment work better.
Washington D.C., District of ColumbiaAges 18 years+ - NCT06660511RecruitingEarly Phase 1
Combination therapy for HER2-positive platinum-resistant ovarian cancer
This trial tests a combination of two drugs—Disitamab Vedotin and Anlotinib—for patients with ovarian cancer that has come back after platinum chemotherapy. It is designed for people whose tumors show a specific protein called HER2, and it aims to see if the combination is safe and effective.
Changsha, HunanAges 18 years+ - NCT07675070Recruiting
Temozolomide (Amitzo) for grade III or IV brain tumors
This trial studies a new form of the chemotherapy drug temozolomide (called Amitzo) in people with aggressive brain tumors (grade III or IV gliomas). It aims to see if the drug is safe and effective, and is for patients who need treatment for a new diagnosis or for tumors that have come back after standard care.
TehranAges 18–80 - NCT07676877RecruitingPhase 1
Low-dose radiation before CAR-T therapy for large B-cell lymphoma
This trial adds a small, whole-body dose of radiation to the standard preparation before CAR-T cell therapy (tisagenlecleucel). The goal is to improve the treatment's effectiveness for patients with relapsed or refractory large B-cell lymphoma.
Columbus, OhioAges 18 years+ - NCT07675980RecruitingPhase 2/Phase 3
Thymosin-α1 for repeated IVF failure
This trial tests whether a drug called thymosin-α1 can help women who have had two or more failed embryo transfers with genetically normal embryos. It aims to improve the chances of successful implantation.
Abu DhabiAges 18–40 - NCT06674343RecruitingPhase 3
Furmonertinib for advanced lung cancer with EGFR mutations
This trial tests a higher dose of furmonertinib (160mg) as a first treatment for advanced non-small cell lung cancer that has specific EGFR mutations (19Del or L858R). It aims to see if this drug can help shrink tumors and delay disease progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07656818Recruiting
Cold plasma to lower risk of chronic subdural hematoma coming back
This trial tests if a special cold plasma treatment applied during surgery can reduce the chance of a chronic subdural hematoma (a slowly growing blood collection on the brain) from returning. It may help people who already need surgery for this condition.
Ocoyoacac, State of MexicoAges 18 years+ - NCT07640295RecruitingPhase 1/Phase 2
New drug plus chemo for advanced pancreatic cancer with KRAS mutation
This study tests a new drug combined with chemotherapy for people with pancreatic cancer that has spread and has a KRAS gene mutation. It may help shrink tumors or slow their growth.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07645690RecruitingEarly Phase 1
CD70 CAR-T Cell Therapy for Advanced Kidney Cancer
This early-stage trial tests a new type of cell therapy called CD70 CAR-T for advanced kidney cancer (clear cell renal cell carcinoma) that has spread or cannot be surgically removed. The therapy uses cells from your own immune system that are genetically modified to recognize and attack cancer cells.
BeijingAges 18–75 - NCT05652374RecruitingPhase 4
Gag therapy for repeat bladder infections, compared to standard antibiotics
This trial tests a therapy (called GAG therapy) to prevent repeat urinary tract infections (UTIs) in adult women. It compares how similar the results are to a well-known antibiotic standard (nitrofurantoin) to see if it works reliably.
Nijmegen, GelderlandAges 18 years+ - NCT07629258RecruitingPhase 1
Testing GW01-200 tablets in advanced cancer patients
This is an early-stage trial testing a new drug called GW01-200 in people with advanced solid tumors or blood cancers that have gotten worse despite standard treatment. The study aims to find the right dose and see how well the drug works and is tolerated.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07627698RecruitingPhase 1/Phase 2
CAR-NK Cell Therapy for Advanced Melanoma
This trial tests engineered immune cells (CAR-NK cells) designed to target two markers found on melanoma cells. The goal is to help patients with melanoma that has spread or cannot be surgically removed and has not responded to or is unsuitable for standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT06685276RecruitingPhase 2
Combination therapy for advanced colorectal cancer
This trial tests a combination of three drugs (fruquintinib, chidamide, and sintilimab) for people with a specific type of metastatic colorectal cancer that has not responded to at least two prior treatments. It aims to see if this combination is safe and effective.
BeijingAges 18–75
Hear when a new Recurrent or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic solid tumors?
- Yes. Clin2 currently lists 3,299 recruiting recurrent or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.